Nexstim Plc provides encouraging results of the initial pilot study in severe depression at Kuopio University Hospital
03 mars 2021 02h00 HE | Nexstim Oyj
Company announcement, Inside information, Helsinki, 3 March 2021 at 9.00 am (EET)  Nexstim Plc provides encouraging results of the initial pilot study in severe depression at Kuopio University...
Nexstim Oyj esittää rohkaisevat tulokset Kuopion yliopistollisen sairaalaan vakavan masennuksen hoidon alustavasta pilottitutkimuksesta
03 mars 2021 02h00 HE | Nexstim Oyj
Yhtiötiedote, sisäpiiritieto, Helsinki, 3.3.2021 klo 9.00 (EET)    Nexstim Oyj esittää rohkaisevat tulokset Kuopion yliopistollisen sairaalaan vakavan masennuksen hoidon alustavasta...
Nexstim Abp lämnar uppmuntrande resultat från den första pilotstudien i svår depression vid Kuopio universitetssjukhus
03 mars 2021 02h00 HE | Nexstim Oyj
Företagsmeddelande, insiderinformation, Helsingfors, 3 mars 2021 kl. 9.00 (EET)   Nexstim Abp lämnar uppmuntrande resultat från den första pilotstudien i svår depression vid Kuopio...
Transformational book offers an approach to harnessing chaos that will enable you to transform your life and thrive
18 févr. 2021 00h00 HE | Balboa Press
FAIRFAX, Va., Feb. 18, 2021 (GLOBE NEWSWIRE) -- “The trauma I faced after the birth of my third baby that left me with six weeks to live was a transformational time in my life.  I was determined to...
20/20 Global, Inc. PsyTech the World’s Most Recognized Psychedelic Conference to Host Live Webinar on New Approaches to Ketamine-Assisted Treatment Wednesday, January 27th 2021 at 12:00 EST
26 janv. 2021 08h30 HE | 20/20 Global, Inc.
MIAMI, Jan. 26, 2021 (GLOBE NEWSWIRE) -- 20/20 Global, Inc., (OTC Pink: TWGL) (the “Company”) announced today an upcoming complimentary Psychedelic Industry webinar for investors and interested...
brsf.png
Brain Scientific, Creator of Next Gen Neurology Technologies, Announces Regulation A+ Offering
15 déc. 2020 08h30 HE | Brain Scientific Inc.
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- Brain Scientific Inc. (OTCQB: BRSF), a neurology-focused medical device and software company, today announced it has launched a...
logo.png
Nexstim Has Received Two New NBT® System Purchase Orders in the United States
10 déc. 2020 05h30 HE | Nexstim Oyj
Press release, Helsinki, 10 December 2020 at 12.30 pm (EET) Nexstim Has Received Two New NBT® System Purchase Orders in the United States Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company")...
logo.png
Nexstim Has Received Two Orders for NBS Systems with SmartFocus® nTMS in Germany
09 déc. 2020 02h30 HE | Nexstim Oyj
Press release, Helsinki, 9 December 2020 at 9.30 am (EET) Nexstim Has Received Two Orders for NBS Systems with SmartFocus® nTMS in Germany Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company")...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation
08 déc. 2020 06h00 HE | Axsome Therapeutics, Inc.
68% reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4 Resolution of suicidal ideation achieved by 60% of patients by Week 1, and 78% by Week 4 Effects consistent with...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression
02 déc. 2020 06h00 HE | Axsome Therapeutics, Inc.
Rapid and substantial improvement in depressive symptoms achieved by 44% of patients at 2 weeks, 67% at 6 weeks (MADRS response), and sustained with long-term treatment Rapid and substantial...